Current and future trends in clostridioides (clostridium) difficile infection management

Area of Science:

• Infectious Diseases
• Microbiology
• Immunology

Background:

• Clostridioides difficile infection (CDI) management is shifting towards prevention of initial and recurrent episodes.
• Antibiotic treatments contribute to CDI and recurrent CDI (rCDI) by disrupting gut microbiota.

Purpose of the Study:

• To review current and emerging strategies for preventing primary and recurrent Clostridioides difficile infection.
• To compare the mechanisms, timelines, and durability of various preventive approaches.

Main Methods:

• Review of novel therapeutics including narrow-spectrum antibiotics, immunologics (monoclonal antibodies, vaccines), microbiome restoration (FMT, biotherapeutics), and non-toxigenic C. difficile (NTCD).
• Categorization of strategies based on their target: primary CDI prevention or rCDI reduction.
• Analysis of the onset and duration of preventive benefits for each approach.

Main Results:

• Newer antibiotics, monoclonal antibodies, and FMT primarily target rCDI.
• Vaccines and gut microbiota modulation aim to prevent primary CDI.
• Biotherapeutics can be used for both primary and recurrent CDI prevention.

Conclusions:

• Monoclonal antibodies, FMT, and biotherapeutics offer rapid but temporary protection.
• Vaccines provide slower but potentially long-lasting immunity against CDI.
• Combining rapid-acting (FMT, biotherapeutics) with durable (vaccines) strategies may offer comprehensive CDI prevention.